SCHEMBL19970845

SCHEMBL19970845

COC(=O)c1ccc(COc2ccccc2CN2CCN(C(=O)c3ccc4nc(C(c5ccccc5)c5ccccc5)[nH]c4c3)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
HTT P42858 2/20 0.42
MAPK14 Q16539 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
USP2 O75604 2/20 0.40
MAPK1 P28482 1/20 0.40
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
FAAH O00519 1/20 0.40
MGLL Q99685 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PDE4A P27815 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970843 0.94 LMNA (0.44) LMNAALDH1A1KDM4EHTTMAPK14
SCHEMBL19970803 0.93 MEN1 (0.43) LMNAALDH1A1KDM4EFAAHMEN1
SCHEMBL19970802 0.88 MEN1 (0.43) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL19970846 0.87 MGLL (0.50) LMNAALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL19970732 0.84 ACACB (0.52) LMNAALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL19970796 0.82 ACACB (0.51) LMNAALDH1A1KDM4EHTTHSD17B10
SCHEMBL23843052 0.81 ACACB (0.47) SMN1; SMN2USP2TSHRPDE4APDE4B
SCHEMBL19970844 0.81 LMNA (0.46) LMNAALDH1A1KDM4EHTTMAPK14
SCHEMBL19982681 0.79 HDAC6 (0.50) LMNAALDH1A1KDM4ESMN1; SMN2PKM
SCHEMBL19970731 0.78 ACACB (0.45) LMNAALDH1A1KDM4EHTTMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS LMNA 614/4885ALDH1A1 1822/4885KDM4E 1873/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS LMNA 614/4885ALDH1A1 1822/4885KDM4E 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.